04.07.26 -- Ever Wonder What Running A $50B Capital Facilities Project Feels Like?

Drug developers must successfully navigate the path to market, under the growing pressure of regulation and competition, and while carefully managing technical and financial risk.

Complex supply chains and fragmented systems slow batch release, delaying patient access and revenue goals. Learn how automation and centralized data improve compliance and accelerate delivery.

Discover key strategies for overcoming challenges in the industrial-scale production of ionizable and PEG lipids to optimize mRNA vaccine formulation and address critical manufacturing requirements.

To keep pace with surging GLP-1 demand, pharma needs partners that can rapidly scale injectable production while maintaining flexibility, quality, and regulatory rigor.

What makes the keying in tablet compression tooling, specifically in tablet punches, so important to the tablet manufacturing processes?

Manual QbD methods slow timelines and increase risk. See how intelligent, digital frameworks are helping CMC teams improve quality, accelerate submissions, and meet rising regulatory expectations.

A solvent‑free, fusion‑based approach streamlines amorphous solid dispersion development, enabling rapid early screening, improved performance, and sustainable manufacturing.

Advanced IV bag inspection technologies ensure patient safety and regulatory compliance. Read more about automated leak detection and quality control innovations to optimize your business.

Experts address key USP <665> questions, including risk assessment, testing approaches, extractables and leachables, and practical challenges in implementing single‑use systems in manufacturing.

Maintaining a cleanroom facility that remains safe for your workers – and where the therapeutics they produce remain safe for patients – can ease your compliance concerns.

Advanced NGS bioinformatics pipelines and curated viral databases enhance the detection of adventitious agents. Examine how cloud-based protocols ensure rigorous safety assessments.

A fully integrated single‑site model unifies development, manufacturing, formulation, fill‑finish, and quality oversight to reduce handoff risk and speed progression from API to sterile drug product.

To accelerate COVID-19 vaccine production, a leading biologics contract manufacturer sought high-speed labeling machines that could be rapidly deployed.